Eli Lilly to Acquire AtaiBeckley for up to $3.8B, Betting Big on Psychedelic Medicine

Eli Lilly and Company has agreed to acquire AtaiBeckley Inc., a clinical-stage biotech developing psychedelic-based therapies for mental illness, in a deal worth up to roughly $3.8 billion, the companies announced on July 16, 2026. It is one of the largest bets a major pharmaceutical company has made on psychedelic medicine to date.

The Terms

Lilly is paying $6.75 per share in cash upfront — about $2.8 billion in aggregate equity value — a premium of roughly 40% over AtaiBeckley’s 30-day volume-weighted average price as of July 15, 2026.

Shareholders can receive up to a further $2.50 per share (about $1.0 billion) through contingent value rights (CVRs) tied to specific milestones:

• $1.00/share upon initiation of a Phase 3 trial of VLS-01;
• $0.50/share upon US approval and DEA rescheduling of BPL-003; and
• $1.00/share upon US approval and DEA rescheduling of VLS-01.

The acquisition is expected to close in Q3 2026, subject to stockholder approval.

What Lilly Is Buying

AtaiBeckley’s lead asset is BPL-003 (mebufotenin benzoate), a synthetic form of 5-MeO-DMT delivered intranasally, in development for treatment-resistant depression — the millions of patients whose depression persists after multiple therapies have failed.

In a Phase 2b study, BPL-003 produced “rapid and durable reductions in depressive symptoms following an in-clinic visit lasting approximately two hours on average, with beneficial effects persisting for months.” It has been granted FDA Breakthrough Therapy Designation and has moved into Phase 3.

Behind it is VLS-01, a buccal-film formulation of DMT, currently in Phase 2b — the reason two of the three CVR milestones are tied to its progress. AtaiBeckley describes its broader pipeline as rapid-acting neuroplastogens: compounds intended to treat psychiatric illness at its biological root rather than only masking symptoms.

What They’re Saying

“Treatment-resistant depression persists even after multiple treatments have failed. Millions of people are still searching for relief,” said Carole Ho, Lilly EVP and President of Neuroscience, framing the need for “a therapy that works.”

“Across our portfolio, we’re seeking to demonstrate that psychiatric illness is treatable at its biological root, not just its symptoms,” said Srinivas Rao, AtaiBeckley’s co-founder and CEO.

“Joining Lilly gives this pipeline, and the patients waiting for it, the benefit of the resources and scale Lilly has to potentially advance therapies faster,” said Christian Angermayer, AtaiBeckley’s founder and chairman — a figure well known in longevity and biotech investing circles.

Why It Matters

The deal is a milestone for a field that has spent a decade moving from the fringes toward regulated medicine. By acquiring a Phase 3 psychedelic asset, Lilly is signaling that big pharma now sees this category as a serious commercial and clinical opportunity — and positions it to compete in a mental-health market where Johnson & Johnson’s esketamine (Spravato) has been an early mover.

The structure of the deal is also telling. The heavy use of CVRs tied to DEA rescheduling underscores what makes psychedelics unlike ordinary drugs: even with strong trial data and FDA approval, these are controlled substances whose commercial path depends on regulatory reclassification. And the “two-hour supervised in-clinic visit” model points to the real-world challenge ahead — delivering a therapy that isn’t a simple daily pill, but a monitored medical experience.

---

The deal at a glance

• Acquirer: Eli Lilly and Company
• Target: AtaiBeckley Inc. (clinical-stage psychedelic/neuroscience biotech)
• Value: $6.75/share cash ($2.8B) upfront, plus up to $2.50/share ($1.0B) in CVRs — up to ~$3.8B total; ~40% premium
• Lead asset: BPL-003 (mebufotenin benzoate), intranasal synthetic 5-MeO-DMT for treatment-resistant depression; Breakthrough Therapy Designation; Phase 3 initiated
• Also: VLS-01, buccal-film DMT, Phase 2b
• Expected close: Q3 2026, subject to stockholder approval

Details and quotes drawn from the companies’ joint press release dated July 16, 2026. Deal completion, milestone payments, and clinical outcomes are subject to regulatory, stockholder, and development risks; forward-looking figures may not be realized.